The Effect of a New Vaginal Cream (A Persian Medicine Product) on Subjective Symptoms of Vulvovaginal Atrophy in Breast Cancer Survivors
| Author | Maryam Radmanesh | en |
| Author | Mona Malekzadeh | en |
| Author | Ghazaleh Heidarirad | en |
| Author | Mozhgan Mehri-Ardestani | en |
| Author | Farid Zayeri | en |
| Author | Mojgan Tansaz | en |
| Orcid | Mona Malekzadeh [0000-0003-2908-7317] | en |
| Orcid | Ghazaleh Heidarirad [0000-0003-4301-5918] | en |
| Orcid | Farid Zayeri [0000-0002-7791-8122] | en |
| Issued Date | 2022-06-30 | en |
| Abstract | Background: Vulvovaginal atrophy (VVA) usually occurs during and after menopause due to low estrogen levels and can cause frustrating symptoms. Existing treatments such as estrogen compounds have undesired side effects. Objectives: This study was conducted to assess the effectiveness of a chicken tallow product for vaginal use on subjective symptoms of VVA in women with breast cancer. Methods: Menopause induced by chemical drugs with subjective symptoms of VVA were selected from the Oncology-Radiotherapy Clinic of Shohadaye Tajrish Hospital between March and July 2020. Informed consent was obtained. Patients were instructed to apply 5g cream every other night before bedtime for 2 weeks, and 2 nights a week for the next 2 weeks and stop the medication. Patients were assessed at the time of initiation of medication, and 2, 4, 6, and 8 weeks after initiation of the trial, and VVA subjective symptoms were assessed. VVA subjective symptom score (VVA-SSS) form was used to assess itching, burning, dryness, and dyspareunia, using a 5-point Likert scale. Data were, then, analyzed. Results: Fifty women were included in the study (age above 18 years). All 5 monitored indices (itching, burning, dryness, dyspareunia, and VVA subjective symptoms score) diminished after initiation of intervention and reached a minimum level after 4 weeks of intervention (1.10 ± 1.16 baseline to 0.04 ± 0.20 at 4 weeks for itching, 1.42 ± 1.09 to 0.04 ± 0.20 for burning, 2.68 ± 0.91 to 0.30 ± 0.54 for dryness, 2.96 ± 0.88 to 0.50 ± 0.61 for dyspareunia, and 8.12 ± 2.70 to 0.86 ± 1.07 for VVA-SSS). During the 4 weeks following discontinuation of treatment, the symptoms slightly increased but remained significantly lower than the baseline (P-value < 0.001 for all 5 indices at all monitored time points). Conclusions: The proposed treatment, rooted in Persian traditional medicine, may offer a safe and effective treatment for VVA symptoms in BCS. | en |
| DOI | https://doi.org/10.5812/ijcm-120193 | en |
| Keyword | Atrophy | en |
| Keyword | Menopause | en |
| Keyword | Cancer Survivors | en |
| Keyword | Traditional Medicine | en |
| Publisher | Brieflands | en |
| Title | The Effect of a New Vaginal Cream (A Persian Medicine Product) on Subjective Symptoms of Vulvovaginal Atrophy in Breast Cancer Survivors | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijcm-15-6-120193.pdf
- Size:
- 519.25 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF